THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Laurent Peyrin-Biroulet  ¹     Axel Dignass  ²     William Sandborn  ³     Kuan-Hsiang G. Huang  ⁴     Matthew Germinaro  ⁴     Rebbecca Wilson  ⁴     Hongyan Zhang  ⁴     Baili CHEN  ⁵     Minhu Chen  ⁵     Tadakazu Hisamatsu  ⁶     Brian G. Feagan  ⁷     Julian Panés  ⁸     Gary Lichtenstein  ^9    
1 Nancy University Hospital, Vandoeuvre-les-Nancy, France
² Agaplesion Markus Krankenhaus, Frankfurt/ Main, Germany
³ University of California San Diego, San Diego, United States
⁴ Janssen Research & Development, LLC, Spring House
⁵ The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
⁶ Kyorin University, Tokyo, Japan
⁷ Alimentiv Inc., London, Canada
⁸ Hospital Clínic Barcelona, Barcelona, Spain
⁹ University of Pennsylvania School of Medicine, Merion Station, United States

Session
Clinical trials in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)